Market overview
The global cell culture market is worth USD 23.9 bn in 2026 and is forecast to reach USD 51.5 bn by 2036, growing at a 8.0% CAGR. United States is the largest country market and Vessels and consumables is the largest by product segment.
| Scope | Consumables for growing cells in the laboratory and in biomanufacturing: media, sera, supplements, reagents, flasks, plates and bags, excluding instruments. |
|---|---|
| Industry | Healthcare |
| Value 2025 | USD 22.0 bn |
| Value 2026 | USD 23.9 bn |
| Value 2036 | USD 51.5 bn |
| CAGR 2026-2036 | 8.0% |
| Volume 2026 | 3,760 million units |
| Volume 2036 | 7,349 million units |
| Average price 2026 | USD 6.35 per unit |
| Report price | Starts from USD 1,999 |
| Published | November 2026 |
Request a free sample of this report
Cell Culture market size and forecast, 2026-2036
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Year | Market value |
|---|---|
| 2026 | USD 23.9 bn |
| 2027 | USD 25.8 bn |
| 2028 | USD 27.8 bn |
| 2029 | USD 30.1 bn |
| 2030 | USD 32.5 bn |
| 2031 | USD 35.1 bn |
| 2032 | USD 37.9 bn |
| 2033 | USD 40.9 bn |
| 2034 | USD 44.2 bn |
| 2035 | USD 47.7 bn |
| 2036 | USD 51.5 bn |
Cell Culture market segmentation
By product
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Media and supplements | 32.0% | 32.3% | USD 7.6 bn | 8.1% |
| Sera | 12.0% | 9.6% | USD 2.9 bn | 5.6% |
| Reagents | 22.0% | 22.2% | USD 5.3 bn | 8.1% |
| Vessels and consumables | 34.0% | 35.9% | USD 8.1 bn | 8.6% |
By end use
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Biopharma bioprocessing | 48.0% | 51.1% | USD 11.5 bn | 8.7% |
| Academic and research | 24.0% | 16.8% | USD 5.7 bn | 4.2% |
| Cell and gene therapy | 14.0% | 21.3% | USD 3.3 bn | 12.6% |
| Diagnostics and vaccines | 14.0% | 10.8% | USD 3.3 bn | 5.2% |
By consumables type
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Sera | 20.0% | 16.0% | USD 4.8 bn | 5.6% |
| Media | 30.0% | 30.0% | USD 7.2 bn | 8.0% |
| Reagents and supplements | 24.0% | 24.0% | USD 5.7 bn | 8.0% |
| Vessels and plates | 26.0% | 30.0% | USD 6.2 bn | 9.6% |
By cell source
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Mammalian | 70.0% | 68.0% | USD 16.7 bn | 7.7% |
| Insect | 8.0% | 9.0% | USD 1.9 bn | 9.3% |
| Microbial | 12.0% | 12.0% | USD 2.9 bn | 8.0% |
| Stem and primary cells | 10.0% | 11.0% | USD 2.4 bn | 9.0% |
By format
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Adherent culture | 40.0% | 34.0% | USD 9.5 bn | 6.3% |
| Suspension culture | 48.0% | 52.0% | USD 11.5 bn | 8.9% |
| 3D and organoid culture | 12.0% | 14.0% | USD 2.9 bn | 9.7% |
Top 25 countries for cell culture by revenue
Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 86.5% of 2026 revenue and the 25 countries below together hold 96.1%.
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| # | Country | Value 2026 | Share 2026 | Value 2036 | CAGR 2026-36 |
|---|---|---|---|---|---|
| 1 | United States | USD 9.1 bn | 38.0% | USD 18.3 bn | 7.3% |
| 2 | China | USD 2.9 bn | 12.0% | USD 8.0 bn | 10.8% |
| 3 | Germany | USD 1.9 bn | 8.0% | USD 3.7 bn | 6.7% |
| 4 | United Kingdom | USD 1.2 bn | 5.0% | USD 2.3 bn | 6.9% |
| 5 | Japan | USD 1.2 bn | 5.0% | USD 2.1 bn | 5.9% |
| 6 | Switzerland | USD 955 mn | 4.0% | USD 1.9 bn | 7.2% |
| 7 | France | USD 955 mn | 4.0% | USD 1.9 bn | 6.9% |
| 8 | South Korea | USD 955 mn | 4.0% | USD 2.4 bn | 9.8% |
| 9 | India | USD 835 mn | 3.5% | USD 2.5 bn | 11.7% |
| 10 | Singapore | USD 716 mn | 3.0% | USD 1.6 bn | 8.7% |
| 11 | Netherlands | USD 391 mn | 1.6% | USD 825 mn | 7.7% |
| 12 | Denmark | USD 353 mn | 1.5% | USD 747 mn | 7.8% |
| 13 | Italy | USD 296 mn | 1.2% | USD 629 mn | 7.8% |
| 14 | Spain | USD 215 mn | 0.9% | USD 454 mn | 7.8% |
| 15 | Australia | USD 193 mn | 0.8% | USD 412 mn | 7.9% |
| 16 | Canada | USD 150 mn | 0.6% | USD 320 mn | 7.8% |
| 17 | Belgium | USD 136 mn | 0.6% | USD 289 mn | 7.8% |
| 18 | Israel | USD 124 mn | 0.5% | USD 263 mn | 7.8% |
| 19 | Brazil | USD 105 mn | 0.4% | USD 247 mn | 8.9% |
| 20 | Taiwan | USD 88 mn | 0.4% | USD 206 mn | 8.8% |
| 21 | Ireland | USD 62 mn | 0.3% | USD 134 mn | 8.0% |
| 22 | Sweden | USD 48 mn | 0.2% | USD 103 mn | 8.0% |
| 23 | Austria | USD 48 mn | 0.2% | USD 103 mn | 8.0% |
| 24 | Russia | USD 43 mn | 0.2% | USD 103 mn | 9.1% |
| 25 | Poland | USD 31 mn | 0.1% | USD 72 mn | 8.8% |
| Rest of world | USD 938 mn | 3.9% | USD 1.9 bn | 7.3% |
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
Competitive landscape
Group 1: Global leaders
- Thermo Fisher Scientific
- Merck KGaA
- Danaher
- Corning
- Sartorius
- Cytiva
Group 2: Regional and specialist players
- Lonza
- FUJIFILM Irvine Scientific
- Eppendorf
- Avantor
- Becton Dickinson
- Greiner Bio-One
- Miltenyi Biotec
- Takara Bio
- STEMCELL Technologies
Group 3: Emerging and niche players
- HiMedia Laboratories
- PromoCell
- Bio-Techne
- PAN-Biotech
- Capricorn Scientific
- Wuhan Procell
Research methodology
Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the cell culture market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.
The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 8.0% is calculated from the resulting values.
The market is divided by product, by end use, by consumables type, by cell source, by format. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.
Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.
Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.
Frequently asked questions
How big is the cell culture market?
The global cell culture market is estimated at USD 22.0 bn in 2025 and USD 23.9 bn in 2026.
How fast will the cell culture market grow?
It is forecast to reach USD 51.5 bn by 2036, a compound annual growth rate of 8.0% from 2026, an increase of USD 27.7 bn.
Which country is the largest market for cell culture?
United States is the largest market by revenue at USD 9.1 bn in 2026, 38.0% of the global total. The three largest countries together hold 58.0%.
Which country is growing fastest?
Among the ten largest markets, India is growing fastest at 11.7% a year from 2026 to 2036.
Which cell culture segment is largest?
In the by product split, Vessels and consumables is the largest segment with 34.0% of 2026 revenue.
Who are the leading cell culture companies?
Global leaders include Thermo Fisher Scientific, Merck KGaA, Danaher, Corning.
Need the full report?
Request a sample to see the structure, tables and country detail.
Request a free sampleRelated markets in Healthcare
- Oral Drug DeliveryUSD 22.6 bn · 7.5% CAGR
- Remote Patient MonitoringUSD 25.7 bn · 16.0% CAGR
- Biopharmaceutical LogisticsUSD 21.7 bn · 9.0% CAGR
- Pharmaceutical Cold ChainUSD 21.6 bn · 8.0% CAGR
- Drug Discovery ServicesUSD 26.4 bn · 10.5% CAGR
- Wound CareUSD 26.5 bn · 6.0% CAGR
- SyringeUSD 21.2 bn · 6.5% CAGR
- NanomedicineUSD 20.1 bn · 9.0% CAGR